

# Elisabet I Nielsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7527942/publications.pdf>

Version: 2024-02-01

39  
papers

1,557  
citations

430442

18  
h-index

315357

38  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1570  
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics of cefotaxime in intensive care patients. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 251-258.	0.8	5
2	Continuous infusion of piperacillinâ€tazobactam significantly improves target attainment in children with cancer and fever. <i>Cancer Reports</i> , 2022, 5, e1585.	0.6	2
3	Imitation of $\beta$ -lactam binding enables broad-spectrum metallo- $\beta$ -lactamase inhibitors. <i>Nature Chemistry</i> , 2022, 14, 15-24.	6.6	39
4	Changes in critical inhaler technique errors in inhaled COPD treatment â€“ A one-year follow-up study in Sweden. <i>Respiratory Medicine</i> , 2022, 197, 106849.	1.3	3
5	Research priorities towards precision antibiotic therapy to improve patient care. <i>Lancet Microbe</i> , The, 2022, 3, e795-e802.	3.4	17
6	Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 5.	1.1	7
7	From Therapeutic Drug Monitoring to Modelâ€Informed Precision Dosing for Antibiotics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 928-941.	2.3	131
8	Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patientsâ€™ Use of Health Care. <i>JAMA Network Open</i> , 2021, 4, e216303.	2.8	22
9	Quantitation of seven sedative and analgesic drugs in whole blood from intensive care patients using liquid chromatography mass spectrometry. <i>Toxicologie Analytique Et Clinique</i> , 2021, 33, 327-327.	0.1	1
10	A novel mechanism-based pharmacokineticâ€pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against $\beta$ -lactamase-producing Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 400-408.	1.3	14
11	Extension of Pharmacokinetic/Pharmacodynamic Time-Kill Studies To Include Lipopolysaccharide/Endotoxin Release from <i>Escherichia coli</i> Exposed to Cefuroxime. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
12	Combination of polymyxin B and minocycline against multidrug-resistant <i>Klebsiella pneumoniae</i> : interaction quantified by pharmacokinetic/pharmacodynamic modelling from in vitro data. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105941.	1.1	13
13	Intervention fidelity and process outcomes of medication reviews including postâ€discharge followâ€up in older hospitalized patients: Process evaluation of the MedBridge trial. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1021-1029.	0.7	6
14	Pharmacodynamics of immune response biomarkers of interest for evaluation of treatment effects in bacterial infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106059.	1.1	18
15	A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6. <i>PLoS ONE</i> , 2019, 14, e0211981.	1.1	15
16	Handling interoccasion variability in modelâ€based dose individualization using therapeutic drug monitoring data. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1326-1336.	1.1	45
17	&lt;p&gt;A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden&lt;/p&gt;. <i>International Journal of COPD</i> , 2019, Volume 14, 2451-2460.	0.9	12
18	The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukinâ€6 and Câ€reactive protein by modelling. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 490-500.	1.1	12

#	ARTICLE	IF	CITATIONS
19	Predicting mutant selection in competition experiments with ciprofloxacin-exposed <i>Escherichia coli</i> . <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 399-406.	1.1	4
20	Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1299-1307.	0.8	13
21	A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 69-79.	0.8	33
22	Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3108-3116.	1.3	23
23	Medication Reviews Bridging Healthcare (MedBridge): Study protocol for a pragmatic cluster-randomised crossover trial. <i>Contemporary Clinical Trials</i> , 2017, 61, 126-132.	0.8	15
24	Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1573-1581.	1.0	20
25	Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 343-353.	1.1	20
26	Evaluation of automated time-lapse microscopy for assessment of in vitro activity of antibiotics. <i>Journal of Microbiological Methods</i> , 2017, 132, 69-75.	0.7	11
27	Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs. <i>Pharmaceutical Research</i> , 2016, 33, 1115-1125.	1.7	46
28	A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant <i>Escherichia coli</i> subpopulations during ertapenem exposure. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2521-2533.	1.3	12
29	Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4869-4877.	1.4	51
30	A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1881-1884.	1.3	26
31	Dynamic interaction of colistin and meropenem on a WT and a resistant strain of <i>Pseudomonas aeruginosa</i> as quantified in a PK/PD model. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1279-1290.	1.3	35
32	A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 3051-3060.	1.3	35
33	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. <i>Pharmaceutical Research</i> , 2014, 31, 754-767.	1.7	67
34	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. <i>Pharmacological Reviews</i> , 2013, 65, 1053-1090.	7.1	248
35	Pharmacokinetic-Pharmacodynamic Model for Gentamicin and Its Adaptive Resistance with Predictions of Dosing Schedules in Newborn Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 179-188.	1.4	71
36	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4619-4630.	1.4	198

#	ARTICLE	IF	CITATIONS
37	Predicting <i>In Vitro</i> Antibacterial Efficacy across Experimental Designs with a Semimechanistic Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1571-1579.	1.4	40
38	Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates. <i>Clinical Pharmacokinetics</i> , 2009, 48, 253-263.	1.6	71
39	Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 128-136.	1.4	143